Moncharmont C, Vallard A, Guy J-B, Prades J-M, Rancoule C, Magné N
Département de radiothérapie, institut de cancérologie Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez, France.
Département de chirurgie ORL, centre hospitalo-universitaire Nord, 42171 Saint-Étienne, France.
Eur Ann Otorhinolaryngol Head Neck Dis. 2017 May;134(3):165-169. doi: 10.1016/j.anorl.2016.12.005. Epub 2016 Dec 27.
There is paucity of data on the efficacy of volumetric modulated arc therapy (VMAT) in head and neck squamous cell carcinoma (HNSCC). The objective of the present study was to investigate outcomes and patterns of recurrence in locally advanced HNSCC treated by VMAT.
A retrospective study included all patients with stage III or IV HNSCC undergoing curative VMAT.
From 2010 to 2013, 130 patients were treated for locally advanced oropharynx (n=55; 42%), hypopharynx (n=38; 29%), larynx (n=22; 17%) or oral cavity (n=15; 12%) SCC. Median age was 60 years (range, 39-85). Median follow-up was 18.1 months (range, 0-43.7). By end of follow-up, 60 patients (46%) had died. Two-year progression-free and overall survival were respectively 63.6% and 77.3% for laryngeal tumors, 60% and 60% for oral cavity tumors, 52.6% and 57.6% for oropharyngeal tumors, and 38.8% and 54.7% for hypopharyngeal tumors. Most recurrences were located within or marginal to radiation therapy fields.
This retrospective analysis is, to our knowledge, the largest study of the efficacy of VMAT in HNSCC. Recurrence patterns and outcomes were consistent with those previously reported for intensity-modulated radiotherapy.
关于容积调强弧形放疗(VMAT)对头颈部鳞状细胞癌(HNSCC)疗效的数据较少。本研究的目的是调查接受VMAT治疗的局部晚期HNSCC的治疗结果和复发模式。
一项回顾性研究纳入了所有接受根治性VMAT治疗的III期或IV期HNSCC患者。
2010年至2013年,130例患者接受了局部晚期口咽癌(n = 55;42%)、下咽癌(n = 38;29%)、喉癌(n = 22;17%)或口腔癌(n = 15;12%)鳞状细胞癌的治疗。中位年龄为60岁(范围39 - 85岁)。中位随访时间为18.1个月(范围0 - 43.7个月)。随访结束时,60例患者(46%)死亡。喉癌的两年无进展生存率和总生存率分别为63.6%和77.3%,口腔癌分别为60%和60%,口咽癌分别为52.6%和57.6%,下咽癌分别为38.8%和54.7%。大多数复发位于放射治疗野内或边缘。
据我们所知,这项回顾性分析是关于VMAT治疗HNSCC疗效的最大规模研究。复发模式和治疗结果与先前报道的调强放疗一致。